Bipar Sciences

BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials for advanced breast, ovarian, and other tumors. Backed by Canaan Partners, Vulcan Capital, PolyTechnos, Asset Management Company, and Quantum Technology Partners, BiPar was acquired by Sanofi-Aventis for roughly $500 million in April 2009 and no longer operates as an independent company. It was surfaced as a Canaan Partners portfolio company and added to the API Evangelist network as a stub; enrichment finds no public developer or API surface.

Bipar Sciences is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Oncology, Pharmaceuticals, and PARP Inhibitors.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalOncologyPharmaceuticalsPARP InhibitorsClinical TrialsAcquiredLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/bipar-sciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: bipar-sciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/bipar-sciences.png
name: Bipar Sciences
description: BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP
  (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials
  for advanced breast, ovarian, and other tumors. Backed by Canaan Partners, Vulcan Capital, PolyTechnos, Asset Management
  Company, and Quantum Technology Partners, BiPar was acquired by Sanofi-Aventis for roughly $500 million in April 2009 and
  no longer operates as an independent company. It was surfaced as a Canaan Partners portfolio company and added to the API
  Evangelist network as a stub; enrichment finds no public developer or API surface.
url: https://raw.githubusercontent.com/api-evangelist/bipar-sciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Oncology
- Pharmaceuticals
- PARP Inhibitors
- Clinical Trials
- Acquired
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence